Combination therapy of anti-PD-1/PD-L1 (BMS-202) and trastuzumab (a drug targeting HER2) significantly reduced the survival rate and invasiveness of breast cancer cells 184. This evidence concerns the gene ERBB2 and breast carcinoma.